Palbociclib (PD-0332991) HCl

Pfizer辉瑞授权 目录号:S1116

Palbociclib (PD-0332991) HCl Chemical Structure

Molecular Weight(MW): 483.99

Palbociclib (PD-0332991) HCl是一种高度选择性的CDK4/6抑制剂,无细胞试验中IC50分别为11 nM/16 nM。它对CDK1/2/5,EGFR,FGFR,PDGFR,InsR等没有抑制活性。Phase 3。

规格 价格 库存 购买数量  
RMB 902.49 现货
RMB 1406.17 现货
RMB 4670.26 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献24篇:

客户使用该产品的11个实验数据:

  • FACS profiles for cell cycle synchronization of HCT116 cells pulsed with EdU. Asynchronous (AS) HCT116 cells were treated with CDK4/6i (Palbociclib, 2 μM) for 20 hours to arrest in G0/G1 (middle panel), followed by a wash in fresh media for 8 hours to release into S phase (right panel).

    Cell, 2018, 174(5):1127-1142. Palbociclib (PD-0332991) HCl purchased from Selleck.

    SK-HEP-1 cells were plated in the presence or absence of the CDK inhibitor (Roscovitine 10 mM; Palbociclib 500 nM). 18 hours after plating, cells were rinsed once with serum-free medium and incubated with delipidated medium containing the CDK inhibitor for 6 hours.

    Cell, 2018, doi:10.1016/j.cell.2018.11.011. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • PD-0332991 causes inhibition of proliferation of EAC cells in a dose-dependent manner. Western blots showing the phosphorylation status of pRB at Ser780 and Ser795 after incubation with 125 nmol/L PD-0332991 for 24 and 72 hours. Reduction in cyclin A expression and the expression of RB2 (p130) tumor suppressor 72 hours after PD-0332991 treatment are shown (bottom). Total pRB (RB1) and actin are loading controls and T293 cell lysate (293) is a positive control for total pRB and phospho-pRB (Ph-RB). E, anchorage-independent growth of the 3 cell lines in the presence or absence (Cnt) of 125 nmol/L PD-0332991 for 3 weeks.

    Clin Cancer Res 2011 17(13), 4513-22. Palbociclib (PD-0332991) HCl purchased from Selleck.

    b, c MelJuso cells were treated for 12–48 h with 1 µM Selumetinib or 5 µM Palbociclib and the cells were fixed, stained with propidium iodide and cell cycle distribution was determined by flow cytometry (b) and whole cell extracts were fractionated by SDS-PAGE, transferred onto PVDF membrane and immuno-blotted with the indicated antibodies (c). Data is from a single experiment representative of three separate experiments with similar results. The data in (b) are mean ± S.D. from a single experiment with three replicate dishes of cell per data point; similar results were obtained in two additional experiments

    Cell Mol Life Sci, 2016, 73(4):883-900. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • (A) Percentage of DN3a cells in S-phase (as gated on DAPI profile) from control (Zfp36l1/2fl/fl) and Zfp36l1/2fl/fl; CD2Cre (DCKO) mice, after 1 d of treatment with vector or palbociclib (drug).

    J Immunol, 2016, 197(7):2673-85. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Patient tumor cell sensitivity to combinatorial treatment with histone deacetylase (HDAC)/cyclin-dependent kinase (CDK) inhibitors in 3-D culture. The effect of each drug or drug combination was assessed by fluorescent dye to identify live (green) and dead cells (red). Cells from breast reduction patients were used as non-cancer control in the assay.

    Pharmacogenomics J 2013 13(1), 94-104. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • The expression of respective proteins in CDK4/6-Rb-apoptosis pathway in cells was examined by Western blot after 3 days of palbociclib treatment.

    Biochim Biophys Acta, 2018, 1864(5 Pt A):1573-1582. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Cdk4 is upregulated in ARMS and mMSCs transfected with PAX7-FKHR fusion gene (MP7F), and can be specifi cally inhibited. D: IF results showing overexpression of cdk4 in MP7F cells compared to parental mMSCs and reduced expression of cdk4 after treatment of MP7F cells with the cdk4 inhibitor, PD-0332991. E: IF results showing MyoD1 expression in parental mMSCs cells, and MP7F cells untreated and after treatment with the cdk4 inhibitor, PD-0332991.

    Clin Transl Oncol 2012 14(3), 197-206 . Palbociclib (PD-0332991) HCl purchased from Selleck.

  • WM3734 melanoma cells were treated by PD-0332991 for 36 hours; melanoma cells treated by Doxorubicin (DXR)  at 0.5 μM is included as a control.

     

     

    Dr. Gao Zhang of University of Pennsylvania. Palbociclib (PD-0332991) HCl purchased from Selleck.

    Serum-deprived T98G glioma cells are restimulated with serum(FBS) with or without 1 μΜ PD-0332991.

     

     

    Dr. Sabine Paternot and Dr Pierre Roger of IRIBHM, ULB, Brussels. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • P16INK4A knockdown in INK4A/ARF-wt human glioma cell LN319 potentiates PDGF-Apromoted anchorage-dependent growth in vitro. Soft agar growth of Ink4a/Arf-deficient mAst and LN444 cells treated with PD0332991. (A) IB analysis. (B) Quantification of soft agar assays. β-actin was used as a loading control in all IB experiments. Data are presented as mean ± s.d. and representative of two independent experiments. **, P < 0.01; ***, P < 0.001

    Dr. Kun-Wei Liu from University of Pittsburgh. Palbociclib (PD-0332991) HCl purchased from Selleck.

产品安全说明书

CDK抑制剂选择性比较

生物活性

产品描述 Palbociclib (PD-0332991) HCl是一种高度选择性的CDK4/6抑制剂,无细胞试验中IC50分别为11 nM/16 nM。它对CDK1/2/5,EGFR,FGFR,PDGFR,InsR等没有抑制活性。Phase 3。
特性 PD-0332991作为有应用前景的工具测定CDK激酶是否具有明显的治疗价值。
靶点
CDK4/CyclinD3 [1]
(Cell-free assay)
CDK4/CyclinD1 [1]
(Cell-free assay)
CDK6/CyclinD2 [1]
(Cell-free assay)
9 nM 11 nM 15 nM
体外研究

PD 0332991 对其他蛋白激酶包括EGFR, FGFR, PGFR, IR等没有抑制效果。 PD 0332991作用于Cdk4时是非ATP竞争性抑制剂。PD 0332991抑制MDA-MB-435乳腺癌细胞,IC50为66 nM,是由于Rb 在Ser780的磷酸化作用下降。PD 0332991抑制胸苷合并到Rb阳性的人类乳腺癌,结肠癌 肺癌,及白血病的DNA中,IC50值为4 nM到0.17 μM。PD 0332991作用于Rb阴性细胞没有抑制效果。PD 0332991作用于MDA-MB-453乳腺癌细胞和结肠-205细胞使细胞积累在G1期。[1]PD 0332991也有效作用于骨髓瘤5T33MM细胞,使细胞对Bortezomib敏感。[2]PD 0332991抑制luminalER-阳性和HER2-增强的乳腺癌细胞系,包括MDA-MB-175 ZR-75-30 CAMA-1 MDA-MB-134 HCC-202 UACC-893 等等。在这些细胞系中,PD 0332991增强Tamoxifen和Trastuzumab 的活性。在MCF7抗Tamoxifen细胞中,PD 0332991也增强tamoxifen 的敏感性。[3] 最新研究显示PD 0332991可以抑制恶性横纹肌样肿瘤(MRT)细胞系包括MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS,且MRT细胞系对PD 0332991敏感性和p16表达呈负相关。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLM13 NGO2NXVMcW6jc3WgRZN{[Xl? NGn5WW0zPCCq MUDJcohq[mm2aX;uJI9nKEOGS{SgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDSZkBxcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMECyJO69VQ>? M16wcVI1PjRzMUCz
COLO205 MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjxSVQ4OiCq MnXERY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{\XO|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjB|NjFOwG0> Mo[xNlQ3PDFzMEO=
U937 NU\OOGU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLWWlc4OiCq M1\Id2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2W|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5zNDFOwG0> MmPtNlQ3PDFzMEO=
MOLM13 NVi0cJJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XxVlczKGh? M4XMUWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTV;MUVE{KGOnbHzzJIhiemKxcnnu[{BHVFR|IFnUSEBufXSjboSgZZN{\XO|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjB7NjFOwG0> MYGyOFY1OTFyMx?=
MOLM13 NFfZfmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;hWlczKGh? M{PzfmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4Sgd49z[W[nbnniMZJme2m|dHHueEBpfW2jbjDNU2xOOTNiY3XscJMh[XO|ZYPz[YQh[XNiaX7jc5Jxd3KjdHnvckBw\iCdM1jdeIh6dWmmaX7lJIlvfG9iRF7BJJdqfGhiSVO1NEBw\iByLkC5OkDPxE1? MY[yOFY1OTFyMx?=
MDA-MB-435 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\sNVI1KGh? NViyT4Q2UUN3ME2wMlE3KM7:TR?= MUCxOVgxOTh|MR?=
K562 MUTDfZRwfG:6aXOgRZN{[Xl? NGqyPIo6PiCq MWLEUXNQ MWnJR|UxRTJizszN MmHhNlQ1OTd3Nk[=
DU145 Ml7kR5l1d3SxeHnjJGF{e2G7 MXK5OkBp MVfEUXNQ MV7JR|UxRTdwNTFOwG0> NETTSnkzPDRzN{W2Oi=>
MDA-MB-231 NWS5XoNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\VXItNOSEQvF2= M{\BeVI1KGh? NETPfZdFVVOR NY\Xb2JTS2WubDDjfYNt\SCjcoLld5Qh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEdzIIDoZZNm NV74dHZkOjR2MUe1OlY>
MCF7 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{j3b|Eh|ryP NX\PcpdPOjRiaB?= Ml;iSG1UVw>? MljFR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JGcyKHCqYYPl NWXPb2NbOjR2MUe1OlY>
MCF7 M3rSOmtqdmG|ZTDBd5NigQ>? NIf4So82KM7:TR?= M2L4TVI1KGh? MmTmSG1UVw>? NUHEVWdqUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBETEt2L3P5Z4xqdkRzIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZicnX0bY5w[myjc4TvcYEheGixc4Doc5J6dGG2aX;uJIF1KFOncke4NC=> M3jkTVI1PDF5NU[2
MDA-MB-231 NV3FbI1CU2mwYYPlJGF{e2G7 NYXxeZJSPSEQvF2= M2nl[lI1KGh? M2HKfmROW09? NF:wUZlKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGNFUzRxY4njcIlvTDFiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC{ZYTpco9jdGG|dH;tZUBxcG:|cHjvdplt[XSrb36gZZQhW2W{N{iw NEW4[WwzPDRzN{W2Oi=>
MDA-MB-231 NVTDN|dMTnWwY4Tpc44hSXO|YYm= NVizPWY1OS1zMDFOwG0> NEPGZ3YzPCCq MXvEUXNQ NWfLRox1\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyCSQWLQJINt\WG4YXfl NXTwbm1KOjR2MUe1OlY>
MCF7 MWjGeY5kfGmxbjDBd5NigQ>? Mo\hNU0yOCEQvF2= MnjONlQhcA>? MnXZSG1UVw>? MX3kc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m|IHHzd4V{e2WmIHHzJHBCWlBiY3zlZZZi\2V? MVOyOFQyPzV4Nh?=
MDA-MB-231 MkiwSpVv[3Srb36gRZN{[Xl? MYewMlUuOSEQvF2= MYe0PEBp NGPZU5RFVVOR Mm\ibIF{KG6xIFPlcIwh[3mlbHWgZZJz\XO2IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDzeYIuTzFicHjhd4U> M1j5VFI1PDF5NU[2
MCF7 NHLQXZFHfW6ldHnvckBCe3OjeR?= M{T3S|AvPS1zIN88US=> MojOOFghcA>? MVrEUXNQ M123T4hieyCwbzDD[YxtKGO7Y3zlJIFzemW|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgd5VjNUdzIIDoZZNm NHfQb5QzPDRzN{W2Oi=>
697 MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXtTWM2OD1zNEiuN|ghdk1? NGWwb4hUSU6JRWK=
P12-ICHIKAWA MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PBXGlEPTB;OU[uNFQhdk1? M3LXcnNCVkeHUh?=
NB69 Mke4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3[5OWlEPTB;MU[xMlghdk1? NIXBWIFUSU6JRWK=
EoL-1 M3jSSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTF6Nz6yOkBvVQ>? M3TqcXNCVkeHUh?=
BHT-101 M4r3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvwTWM2OD1zOUiuNlUhdk1? MVrTRW5ITVJ?
SK-NEP-1 MkHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTJ{MD6wNkBvVQ>? NYTVWZJbW0GQR1XS
MHH-NB-11 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3vUYhVUUN3ME2yNlAvOTlibl2= NETIbWpUSU6JRWK=
AsPC-1 NEHtUZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NID4OGNKSzVyPUK1Nk42OyCwTR?= MV\TRW5ITVJ?
ES1 NUjuXmtHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTJ3Nj6yOUBvVQ>? Mkm1V2FPT0WU
LAMA-84 NYP6ZoZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHyTWM2OD1{NUiuNVkhdk1? NH;ZWYRUSU6JRWK=
MOLT-16 M1Xtemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHqbXRCUUN3ME2yOVgvPDlibl2= NXvOVnFZW0GQR1XS
ES7 NVvrZlgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlruTWM2OD1{N{OuNFkhdk1? M4HTfHNCVkeHUh?=
KY821 Ml3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;QO2FKSzVyPUOxOE4yKG6P NHOxWo9USU6JRWK=
RT-112 M1LqXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTN{MT6wOUBvVQ>? M2DTPXNCVkeHUh?=
HL-60 NEnDRXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfwTWM2OD1|NECuOlYhdk1? MXPTRW5ITVJ?
MOLT-4 NUHUbHFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnR[FREUUN3ME2zOFUvOTNibl2= MmLEV2FPT0WU
KARPAS-45 Mm\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDMTWM2OD1|N{[uNVYhdk1? MYPTRW5ITVJ?
SK-N-AS NXTG[FhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTN6Nz64N{BvVQ>? Mn3nV2FPT0WU
CTB-1 NXe5dnBDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIizVYFKSzVyPUSwOU4xOiCwTR?= NIf6WmhUSU6JRWK=
NKM-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3mNYNKSzVyPUSxNU45QSCwTR?= MoHyV2FPT0WU
HTC-C3 MnOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HlXWlEPTB;NEOyMlk2KG6P MUHTRW5ITVJ?
BE-13 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTR2ND6yO{BvVQ>? M3jtfXNCVkeHUh?=
KOSC-2 MnnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3sVnBKSzVyPUS2Ok46KG6P NGXUS3NUSU6JRWK=
NB14 M3\5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\aeZBKSzVyPUS4N{42QCCwTR?= NIriRmlUSU6JRWK=
CAL-27 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2SwdGlEPTB;NEm0MlU6KG6P NG\H[Y5USU6JRWK=
H9 NVvOSHRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mne1TWM2OD12OUWuOFMhdk1? MkK1V2FPT0WU
RS4-11 MnvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorSTWM2OD13MESuO|Mhdk1? NGjkV2dUSU6JRWK=
PA-1 NFj5UmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2i4SGlEPTB;NUC5Mlg3KG6P MX3TRW5ITVJ?
MV-4-11 MmTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfKTWM2OD13MUOuPFUhdk1? MYrTRW5ITVJ?
OS-RC-2 NH;1fnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTV{MT62NkBvVQ>? NXruNGxxW0GQR1XS
RPMI-8226 NX\DXIx1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLYTWM2OD13Mk[uPFYhdk1? NEXjSlRUSU6JRWK=
HGC-27 NGS0dodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTV4ND65PUBvVQ>? Mmn2V2FPT0WU
CHP-212 Ml;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LaWmlEPTB;NUmzMlU6KG6P NHPLb3lUSU6JRWK=
NB10 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LYcWlEPTB;NUm5MlE5KG6P MVnTRW5ITVJ?
HH MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fYdWlEPTB;NUm5MlQ{KG6P MXTTRW5ITVJ?
EW-16 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\peXlpUUN3ME22NFMvPTJibl2= MX;TRW5ITVJ?
ES8 NISxXYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml2xTWM2OD14MEWuNlEhdk1? MWHTRW5ITVJ?
HAL-01 NFTHN2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NViwSotlUUN3ME22NFUvPjdibl2= MVjTRW5ITVJ?
A204 NVfL[45MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljrTWM2OD14M{OuPVEhdk1? MVTTRW5ITVJ?
MHH-PREB-1 Mn;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\teotKSzVyPU[zOk46QSCwTR?= MUnTRW5ITVJ?
EM-2 NUnHNmtrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWC5eY42UUN3ME22OVAvPjRibl2= NXjwT2EyW0GQR1XS
BV-173 MoD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTZ3Mj60PEBvVQ>? NHvkSFZUSU6JRWK=
ONS-76 M{\RZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHMN3NtUUN3ME22O|cvQDJibl2= NIX6WplUSU6JRWK=
KM-H2 MlfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYruPYZNUUN3ME22PVUvPTRibl2= M2\jVnNCVkeHUh?=
D-263MG NHf4VVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoW0TWM2OD15MUeuNVIhdk1? NXXwdnd2W0GQR1XS
ES3 NYe4OmpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTd{OD65N{BvVQ>? M3PoZ3NCVkeHUh?=
VA-ES-BJ MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTd|Mj6yO{BvVQ>? NYjjVldbW0GQR1XS
NBsusSR M4HtXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTd2Mj65PUBvVQ>? NHj1PZdUSU6JRWK=
NCI-H520 NGD6WWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmr4TWM2OD15NE[uOVIhdk1? NEDGcVNUSU6JRWK=
ES5 NXfNNXdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWL3[VhIUUN3ME23OVIvQCCwTR?= NEHoRoJUSU6JRWK=
T-24 NWrKN4hIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LCfmlEPTB;N{e4MlcyKG6P NGKxRmNUSU6JRWK=
SW962 NFn1Z2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRThyOD62N{BvVQ>? NWLifVlXW0GQR1XS
EW-3 MoXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXtTWM2OD16MEiuO|Yhdk1? NETyVJhUSU6JRWK=
RXF393 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRThzMj63PUBvVQ>? Mli4V2FPT0WU
U251 NVzoVoVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLMOWlOUUN3ME24NVMvQDhibl2= MUTTRW5ITVJ?
CAMA-1 NE\v[HVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTh|Mz65OEBvVQ>? NFiycW5USU6JRWK=
JVM-3 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3ifoFVUUN3ME24OVEvPzhibl2= MWPTRW5ITVJ?
COLO-800 MkH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TwNWlEPTB;OEm3Mlc5KG6P MkX6V2FPT0WU
OVCAR-5 NYr1TWM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\aXGZKSzVyPUmwNE4yKG6P MmHkV2FPT0WU
LB1047-RCC M1f2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjrPIVKSzVyPUmyO{42PiCwTR?= M2LHTXNCVkeHUh?=
SW954 M3T4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzVRW9FUUN3ME25NlkvPDFibl2= M1vCXHNCVkeHUh?=
J-RT3-T3-5 M2rNPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTl|Nj6wOkBvVQ>? M2rHSnNCVkeHUh?=
Mewo MoWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFGyfVdKSzVyPUmzOk43KG6P NVnWRZY6W0GQR1XS
NCI-H1770 NYG0RmpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLmWFh6UUN3ME25OFAvPTVibl2= MXTTRW5ITVJ?
HO-1-N-1 MnvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HJOWlEPTB;OU[yMlgyKG6P NVf5ZllyW0GQR1XS
HSC-3 NHHFXGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGX3S5lKSzVyPUm2Ok41QCCwTR?= NVXjXWFnW0GQR1XS
TYK-nu NGHZU5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\hZnZKSzVyPUm5PE4zPSCwTR?= NG[zfopUSU6JRWK=
KYSE-150 NHjZRYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTFwMECwO|Yh|ryP NUjlSWx1W0GQR1XS
SN12C NYjU[IZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mny4TWM2OD1zLkCwPFc2KM7:TR?= NVjOfWxTW0GQR1XS
MOLT-13 M3qzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MomwTWM2OD1zLkCxOFIyKM7:TR?= NXq4XWVLW0GQR1XS
TE-11 NH3GO5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTFwMES4NVIh|ryP MVLTRW5ITVJ?
DB NY\PR3FQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTFwMEeyO|Mh|ryP NFGzeI9USU6JRWK=
CAL-39 M4fpbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI[4dnJKSzVyPUGuNFc2OjJizszN M2\xZ3NCVkeHUh?=
A3-KAW MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7TeGtKSzVyPUGuNFg1ODhizszN NGj2[VZUSU6JRWK=
CHP-134 M3HXWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTqZoRbUUN3ME2xMlEyQDB5IN88US=> MmjrV2FPT0WU
TGW MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHxTWM2OD1zLkGyN|k2KM7:TR?= M1zKSnNCVkeHUh?=
QIMR-WIL NWTvVpdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfhSG9KSzVyPUGuNVMyOzRizszN M3;lNXNCVkeHUh?=
NCI-SNU-1 MmjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjHTWM2OD1zLkG2N|U1KM7:TR?= NVHHcVFGW0GQR1XS
CGTH-W-1 M2jTT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLLTWM2OD1zLkG3NVg3KM7:TR?= M3vzbXNCVkeHUh?=
MHH-ES-1 M3XqZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3QTWM2OD1zLkG3PVg3KM7:TR?= MkLZV2FPT0WU
LB2241-RCC M{jEVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXDTWM2OD1zLkG4OlIh|ryP MofIV2FPT0WU
ML-2 NWLRVZpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfkTWM2OD1zLkKwO|M1KM7:TR?= MnT1V2FPT0WU
COR-L23 NVrjZYI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTFwMkK5N|Mh|ryP M2rxU3NCVkeHUh?=
BFTC-905 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{n2ZWlEPTB;MT6yOFI3PyEQvF2= M322NnNCVkeHUh?=
Hs-578-T M2qzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTFwMkW4NVch|ryP MmTnV2FPT0WU
KG-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUW5c|ZvUUN3ME2xMlI3Pjh4IN88US=> NG\vdnRUSU6JRWK=
HEL NFz0NYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnnRmVNUUN3ME2xMlI6OzN6IN88US=> MXrTRW5ITVJ?
A549 NEL6PXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHuN4gxUUN3ME2xMlI6Ozl7IN88US=> NGOzVYlUSU6JRWK=
COLO-741 NEn4N|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX76cm5uUUN3ME2xMlMzODh7IN88US=> M2TvO3NCVkeHUh?=
PC-3 NGL0OGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlP3TWM2OD1zLkO1NlIyKM7:TR?= NWm3N5NZW0GQR1XS
HOS M3PabWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\uTWM2OD1zLkO1Nlk3KM7:TR?= MmfIV2FPT0WU
HT-1080 NW[ycppzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn63TWM2OD1zLkO3OVE6KM7:TR?= MlH4V2FPT0WU
TE-8 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvwdnZ[UUN3ME2xMlQyPzd2IN88US=> NH;zSZdUSU6JRWK=
BHY NHnUV3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;Xb2lEPTB;MT60OlkzOyEQvF2= NF\WXW1USU6JRWK=
BB65-RCC NHfRdHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrIV5hZUUN3ME2xMlUxPTJ6IN88US=> MnHuV2FPT0WU
HN NIruUJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTFwNUSwO|Eh|ryP MkHYV2FPT0WU
NCI-H441 NGizRpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvHTWM2OD1zLkW0PVA4KM7:TR?= M4GySXNCVkeHUh?=
RPMI-8866 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjuTWM2OD1zLkW4OVA4KM7:TR?= M2W0dHNCVkeHUh?=
CAL-62 NIDXfXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17XdWlEPTB;MT62NFg3OiEQvF2= NVW5R|R{W0GQR1XS
MG-63 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPVTWM2OD1zLk[xPFE{KM7:TR?= NVmxTmIxW0GQR1XS
SK-LU-1 NUfiNY1lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTITWM2OD1zLk[yNVUzKM7:TR?= M2\zenNCVkeHUh?=
BCPAP M4S5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmr3TWM2OD1zLk[2OFU4KM7:TR?= MkPhV2FPT0WU
22RV1 M4nTfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrpTWM2OD1zLk[3PFQ{KM7:TR?= NWmxNYZXW0GQR1XS
T47D NGnxWHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\0OHVKSzVyPUGuOlgxPjFizszN MmX6V2FPT0WU
MSTO-211H NEHhXJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLjc3RKSzVyPUGuOlk3ODNizszN MXfTRW5ITVJ?
DEL NYHGd415T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPjcoxNUUN3ME2xMlcxOjd|IN88US=> MlfBV2FPT0WU
H4 MlrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHhTWM2OD1zLkezNlEzKM7:TR?= M{\XbXNCVkeHUh?=
CAL-51 NXLEdZI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTFwN{S4OVUh|ryP M3LpTnNCVkeHUh?=
ABC-1 Mn\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTFwN{i1PFIh|ryP Ml6zV2FPT0WU
MZ2-MEL NFTlNZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzUdZIyUUN3ME2xMlc6PTR{IN88US=> Mn7CV2FPT0WU
YKG-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjLOFZKSzVyPUGuPFExPjFizszN MXHTRW5ITVJ?
KM12 MnT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnG3TWM2OD1zLkixOlAzKM7:TR?= M{DIVnNCVkeHUh?=
L-363 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfj[pFKSzVyPUGuPFc1OTJizszN MnzBV2FPT0WU
KU812 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmS2TWM2OD1zLki5NlgzKM7:TR?= M4G0dXNCVkeHUh?=
LOXIMVI NVLRPY5rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;pSFJKSzVyPUGuPVEzOjhizszN MnTsV2FPT0WU
G-401 NXrX[4dmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2juSGlEPTB;MT65NlQzQCEQvF2= MX;TRW5ITVJ?
SW780 NHTobmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjMc2diUUN3ME2xMlk3OjR4IN88US=> M17YPXNCVkeHUh?=
SW872 NX7BcY81T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPBT4pKSzVyPUGuPVg{OyEQvF2= M1rkTXNCVkeHUh?=
NB7 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TVZWlEPTB;MT65PVMzOyEQvF2= MX7TRW5ITVJ?
T98G MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTJwMEC2OlYh|ryP NXvJVGJ3W0GQR1XS
SW1710 NIS2XlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYT5e2tjUUN3ME2yMlA3QTR3IN88US=> NXL1T2RQW0GQR1XS
NCI-H1573 M1PkfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTJwMEeyPVgh|ryP M{TDTHNCVkeHUh?=
KE-37 M1fvfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzUTWM2OD1{LkC4PVUyKM7:TR?= MVfTRW5ITVJ?
786-0 M1;ENmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoToTWM2OD1{LkG1OFM6KM7:TR?= NYizUnhVW0GQR1XS
SAS MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoWyTWM2OD1{LkKwN|c1KM7:TR?= M2rsenNCVkeHUh?=
CAL-54 NFLv[WpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;yNmlEPTB;Mj6yNFQyOyEQvF2= MXTTRW5ITVJ?
SF268 NGjnXG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zIe2lEPTB;Mj6yN|EzOiEQvF2= M4\LfnNCVkeHUh?=
SW620 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHRO5ZKSzVyPUKuNlYyPjlizszN M{HVS3NCVkeHUh?=
MN-60 M1[4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTJwM{GwOkDPxE1? NYTB[mF[W0GQR1XS
EFO-27 MnPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIK5e5dKSzVyPUKuN|IxPThizszN MWrTRW5ITVJ?
NCI-H747 M{\2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jOcWlEPTB;Mj6zNlE6QSEQvF2= MVnTRW5ITVJ?
HCC2218 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUiweI9xUUN3ME2yMlM2Ozd2IN88US=> MX;TRW5ITVJ?
MIA-PaCa-2 MonPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXZfINKSzVyPUKuN|Y1OzdizszN MnyxV2FPT0WU
SJSA-1 M1[5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTJwM{e3PVYh|ryP NHjEeXZUSU6JRWK=
RKO NW\nUlRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\zempKUUN3ME2yMlM5PDl4IN88US=> MX;TRW5ITVJ?
NB6 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrLTWM2OD1{LkSwN|c1KM7:TR?= M2[4[3NCVkeHUh?=
ES4 NV6xbm9UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4C2UmlEPTB;Mj60OVQzOiEQvF2= Ml7tV2FPT0WU
EGI-1 MoHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTtZYFKSzVyPUKuOFY5QDNizszN M1XlSXNCVkeHUh?=
CTV-1 M2fHS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPCTWM2OD1{LkWyO|c{KM7:TR?= MVnTRW5ITVJ?
NCI-H1355 M37IWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTJwNUW5OVEh|ryP M1LUZXNCVkeHUh?=
GT3TKB NX;VPI5DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjPOlRsUUN3ME2yMlU6OTl7IN88US=> MljRV2FPT0WU
SK-HEP-1 M134VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjENYxKSzVyPUKuOVkzPjZizszN MUPTRW5ITVJ?
GAMG M1TGWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTJwNUmzPVQh|ryP M1PGWnNCVkeHUh?=
SK-MES-1 M{ixXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofQTWM2OD1{Lk[xPFA{KM7:TR?= MljyV2FPT0WU
RO82-W-1 MoTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fYemlEPTB;Mj62NlA2PyEQvF2= NXzNc49MW0GQR1XS
ECC10 NWTnNVhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTJwN{CyNFYh|ryP NFPoS5NUSU6JRWK=
MCF7 MljwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvRTWM2OD1{LkexOFY1KM7:TR?= M{j5XXNCVkeHUh?=
D-283MED NVfKPWNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfNPXVrUUN3ME2yMlczPDNizszN Mn3FV2FPT0WU
RPMI-7951 NF7MNJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDqSIZGUUN3ME2yMlc2Pjl2IN88US=> MXLTRW5ITVJ?
Ramos-2G6-4C10 M4nsSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTJwN{ewPVkh|ryP M2nkOXNCVkeHUh?=
KGN MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDrSXpKSzVyPUKuPFE5QDRizszN M1zVc3NCVkeHUh?=
NUGC-3 NGXDWFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDkOpJ5UUN3ME2yMlgzPTB3IN88US=> M2\pW3NCVkeHUh?=
NCI-H292 NIOxfpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rGdGlEPTB;Mj64OVA2OyEQvF2= NUDKNXFDW0GQR1XS
Becker MonaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1Tkd2lEPTB;Mj65OVg{OiEQvF2= MkfRV2FPT0WU
NCI-H1299 NYjneZlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTNwMEWyOlMh|ryP MV7TRW5ITVJ?
ETK-1 NGHrU5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3ORVhKSzVyPUOuNFU1OyEQvF2= MVvTRW5ITVJ?
TK10 NXPXVHA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nRWmlEPTB;Mz6yNFE3PSEQvF2= MVHTRW5ITVJ?
VMRC-RCZ MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHx[5hKSzVyPUOuN|Y1QDhizszN NEPCVmdUSU6JRWK=
YH-13 NEXD[2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrSTWM2OD1|LkS0NFc6KM7:TR?= NWDQUFViW0GQR1XS
DU-145 M2rpZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DUPGlEPTB;Mz60OlI3QSEQvF2= Mn7YV2FPT0WU
SW1088 NWXVVYc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTNwNEe0O{DPxE1? MWTTRW5ITVJ?
HOP-92 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXW1cGVFUUN3ME2zMlUxOzR{IN88US=> NF[wXYhUSU6JRWK=
KP-N-YS Mn76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGixcGlKSzVyPUOuOlIyOzlizszN M{PzR3NCVkeHUh?=
NCI-H460 NXfa[WtMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7aR3VKSzVyPUOuOlY4OyEQvF2= NWmySnlyW0GQR1XS
U-2-OS M4\YOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTNwN{K1N|Uh|ryP M{ewTXNCVkeHUh?=
A101D NHvpd|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILMd45KSzVyPUOuO|Y6OzZizszN MVzTRW5ITVJ?
MDA-MB-231 NHW1S2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDNdXBQUUN3ME2zMlgyQTVzIN88US=> Moe2V2FPT0WU
IST-MES1 M3zJ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILMfoNKSzVyPUOuPFMzKM7:TR?= MljrV2FPT0WU
COR-L105 M3W4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTRwMEG4JO69VQ>? NGjHO3pUSU6JRWK=
NCI-H1437 NXm0dZJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLDTWM2OD12LkCyN|AzKM7:TR?= MYfTRW5ITVJ?
CAL-85-1 NVThV5YyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\uPJBKSzVyPUSuNFI1PjFizszN M2DQbHNCVkeHUh?=
MZ1-PC M3TMOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrhSJVKSzVyPUSuNVg2PTZizszN M2\oenNCVkeHUh?=
VM-CUB-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzTTWM2OD12LkOxNlg1KM7:TR?= MlzpV2FPT0WU
CHL-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7u[GJsUUN3ME20MlMzOTZ7IN88US=> NIC5WWVUSU6JRWK=
MDA-MB-361 M3j2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHYTWM2OD12LkOzNVU{KM7:TR?= NVPPfXZNW0GQR1XS
NCI-H661 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LXdmlEPTB;ND61NFA6OiEQvF2= NW\0W4RJW0GQR1XS
EW-11 M4C3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTRwNUKyN|Eh|ryP M1;XRXNCVkeHUh?=
BEN NIHDUJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvKZ2hKSzVyPUSuOVI5OTVizszN MmLBV2FPT0WU
BFTC-909 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLMPHlKSzVyPUSuOVYzPzVizszN M3:wVnNCVkeHUh?=
NCI-H2087 NXzuPGJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTRwNUixOlQh|ryP M4TncnNCVkeHUh?=
RVH-421 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrLcYM2UUN3ME20MlY3PjlizszN NXzlV3dsW0GQR1XS
P30-OHK NWrEU5NxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrUZ5VKSzVyPUSuOlgxODhizszN NGOzTo9USU6JRWK=
NCI-H28 M{TUeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUCx[|lKUUN3ME20MlgyPjZzIN88US=> M3H6S3NCVkeHUh?=
ES6 MmH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLpV|hKSzVyPUSuPFMxOTZizszN MkHzV2FPT0WU
769-P MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIX2UYJKSzVyPUSuPFU6OjZizszN NXnlN|M6W0GQR1XS
OE33 NIP6WYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlH5TWM2OD12Lki4NVYyKM7:TR?= MmfTV2FPT0WU
SW982 M3G0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYf6U4VOUUN3ME20Mlk2ODZzIN88US=> M1\DbHNCVkeHUh?=
A388 NEjaO3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTDPWRmUUN3ME21MlAzQTh|IN88US=> MonuV2FPT0WU
TI-73 NH\HVIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\QTWM2OD13LkC2NVk1KM7:TR?= Mn7VV2FPT0WU
HCT-116 MmewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnf2TWM2OD13LkC5PFg6KM7:TR?= NVni[5UyW0GQR1XS
HuP-T3 M4rXWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjVTWM2OD13LkG4O|A6KM7:TR?= NV;sTWZMW0GQR1XS
G-402 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTXbWVKSzVyPUWuNVk1OTZizszN NILNZZhUSU6JRWK=
NCI-H1792 M{SxUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\ScGpKSzVyPUWuNlQ3OjJizszN MlfhV2FPT0WU
NCI-H209 M3Tp[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\RTWM2OD13LkK1PVQzKM7:TR?= NUTFNFM3W0GQR1XS
NCI-H1650 NWrFXYZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTVwM{C2N|Qh|ryP MkTrV2FPT0WU
LCLC-97TM1 MkfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTrT5lKSzVyPUWuN|E5ODhizszN NIXNZ3lUSU6JRWK=
S-117 NH[w[XBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLLPYF{UUN3ME21MlM3QTd4IN88US=> NFzoS5FUSU6JRWK=
GI-ME-N M2e2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHq5b|BKSzVyPUWuN|k3QDFizszN NUW5NVZbW0GQR1XS
NCI-H2122 M{DaRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fhcGlEPTB;NT60PVM6PyEQvF2= MWrTRW5ITVJ?
NCI-H1793 M2m2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTVwNke1PVMh|ryP Ml7UV2FPT0WU
C2BBe1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTKTWM2OD13LkewNFg5KM7:TR?= NHrUfJVUSU6JRWK=
TE-12 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1P3TmlEPTB;NT64NFU2PiEQvF2= NU\rXmp[W0GQR1XS
LCLC-103H MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrhUmJKSzVyPUWuPVE4KM7:TR?= MX7TRW5ITVJ?
A673 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTVwOUG5N|Ih|ryP MoG4V2FPT0WU
BB30-HNC NXm5Z4Y3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDtTWM2OD13Lkm4N|Yh|ryP MVTTRW5ITVJ?
SF295 NGCwb4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHtS|FKSzVyPU[uNFA1OjJizszN MXvTRW5ITVJ?
KU-19-19 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\lOmlEPTB;Nj6wNVc{OSEQvF2= MXnTRW5ITVJ?
CFPAC-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHiwTZhKSzVyPU[uNFQ1PDNizszN MV7TRW5ITVJ?
LoVo MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojvTWM2OD14LkC1NFY{KM7:TR?= NFLKW4lUSU6JRWK=
8505C M2TBVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTZwMEe1O|Mh|ryP MWHTRW5ITVJ?
GMS-10 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\pUGlEPTB;Nj6xOVAxOiEQvF2= M2fZZ3NCVkeHUh?=
Ca9-22 MlLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3n4UmlEPTB;Nj6xOlcyKM7:TR?= M{jaRXNCVkeHUh?=
DOK NE\6TGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVroVm1MUUN3ME22MlIzODd{IN88US=> NX7EcG41W0GQR1XS
FADU MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[xPWxKSzVyPU[uNlYxOzlizszN M1TOTHNCVkeHUh?=
BxPC-3 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\KZoNDUUN3ME22MlI4OzJizszN M4jKZnNCVkeHUh?=
CAL-33 NYLLbGZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTZwMkmyNFEh|ryP M3TBOHNCVkeHUh?=
SHP-77 Mn74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFu3b4xKSzVyPU[uN|E2OTJizszN M{[yPXNCVkeHUh?=
LXF-289 M3rS[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnH3TWM2OD14LkOzOFU2KM7:TR?= MVTTRW5ITVJ?
GB-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTCRpNKSzVyPU[uN|gzKM7:TR?= M3TZcXNCVkeHUh?=
KS-1 M4DMZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILhU2VKSzVyPU[uN|g1PDdizszN Ml3rV2FPT0WU
D-502MG NWnjXGhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TETWlEPTB;Nj60NlM4PiEQvF2= MYfTRW5ITVJ?
LAN-6 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXlOmhKSzVyPU[uOVExOjNizszN NFz4dJZUSU6JRWK=
H-EMC-SS M3vEVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfqS5prUUN3ME22MlU3OTR5IN88US=> NXnrZlJQW0GQR1XS
LC-2-ad NWi0[GMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTZwNkCwO|Yh|ryP MXfTRW5ITVJ?
NCI-H1693 NY\OZppZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3:xd2lEPTB;Nj62NlIyPSEQvF2= MX3TRW5ITVJ?
SK-N-FI M2XmeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTZwN{WwOFQh|ryP MY\TRW5ITVJ?
D-423MG NIH3XlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojvTWM2OD14Lke2NVE4KM7:TR?= NVnXT49DW0GQR1XS
KNS-42 NEK3PIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTZwN{ixPVch|ryP NXuxO3N[W0GQR1XS
GCT MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYG3U2tsUUN3ME22Mlk{QCEQvF2= MY\TRW5ITVJ?
DSH1 NEPXWJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjuTWM2OD15LkC2N|Mh|ryP M{fEOXNCVkeHUh?=
D-247MG M{HNfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF63XpNKSzVyPUeuNFc5QDFizszN MYXTRW5ITVJ?
NCI-SNU-5 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3npOmlEPTB;Nz6xPFM4OSEQvF2= NHXSc2hUSU6JRWK=
TE-6 NEnLZ2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TXbmlEPTB;Nz6yNFYxOSEQvF2= NH3uWW5USU6JRWK=
NOMO-1 NXG2WJRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEH2bYtKSzVyPUeuNlIyOjdizszN M3nFdnNCVkeHUh?=
NB17 NF:0XoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDRb5RKSzVyPUeuN|A{ODlizszN M3LifHNCVkeHUh?=
EW-22 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTdwM{SzOFgh|ryP NIjVbpFUSU6JRWK=
EW-13 NFHpeG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTdwM{WxOlIh|ryP M4TlOXNCVkeHUh?=
DOHH-2 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlH5TWM2OD15LkS0NFIh|ryP MVTTRW5ITVJ?
TGBC1TKB NWrvOYxPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2P6bWlEPTB;Nz60PVg6QSEQvF2= MXXTRW5ITVJ?
GR-ST Mm\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHroT5BKSzVyPUeuOVI2QTRizszN NWruN40zW0GQR1XS
KYSE-520 NEDxVVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGi0[2JKSzVyPUeuOVU2OTVizszN Mn\tV2FPT0WU
CAPAN-1 NIjGR3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjaWlA{UUN3ME23MlU6PTFizszN NVH4NJdqW0GQR1XS
HCE-4 M{P2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYq4SJVKUUN3ME23MlYzOjd7IN88US=> MV;TRW5ITVJ?
MLMA NV3ubGpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;vZ2lEPTB;Nz62Nlk2PyEQvF2= Mn\TV2FPT0WU
HT-144 NE\rSmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfuendGUUN3ME23MlY2OzZ6IN88US=> MWrTRW5ITVJ?
KYSE-180 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LJbmlEPTB;Nz63NVE3QSEQvF2= NG\LSplUSU6JRWK=
TE-5 NYO1VINQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XkNmlEPTB;Nz65OVk4OSEQvF2= MoH5V2FPT0WU
IGROV-1 MkDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTdwOUi1OVEh|ryP NYf4Rm1sW0GQR1XS
NCI-H1581 MmiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRThwMEGyJO69VQ>? M{LBNnNCVkeHUh?=
SW1990 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofwTWM2OD16LkC0OlU6KM7:TR?= NUX5bmJ6W0GQR1XS
EFM-19 NIXWR2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRThwMEi1OFUh|ryP NVvjdolKW0GQR1XS
OGR-1 MnS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4q4N2lEPTB;OD60N|AzOyEQvF2= NFLFSmVUSU6JRWK=
U-118-MG M{\QfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkS5TWM2OD16LkSzOFY{KM7:TR?= MX3TRW5ITVJ?
SK-OV-3 NEnzemFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGG2OYNKSzVyPUiuOFY4PjVizszN Moj3V2FPT0WU
KNS-62 NFfafY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\RPWJ5UUN3ME24MlUyPzZzIN88US=> M1TKSnNCVkeHUh?=
GOTO MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrXTnNFUUN3ME24MlU4PjN3IN88US=> NH7mbGNUSU6JRWK=
8305C M3\nOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTrcnpzUUN3ME24MlcxPDh2IN88US=> NHmxbXBUSU6JRWK=
RPMI-2650 M2P2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWP6NGo3UUN3ME24MlcyQTV3IN88US=> MnqxV2FPT0WU
NEC8 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoX0TWM2OD16Lke0N|A4KM7:TR?= NHW2dW5USU6JRWK=
KYSE-450 NXnSU3JuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrGcIhSUUN3ME24Mlg3PTR6IN88US=> MkTMV2FPT0WU
RMG-I MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XIfGlEPTB;OT6xOFA2QCEQvF2= NHuyZYxUSU6JRWK=
CAKI-1 NFPlcodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTlwM{G5O|kh|ryP NVPPPG4xW0GQR1XS
KYSE-510 MoTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHxV3Q5UUN3ME25MlM2Pzd6IN88US=> MYTTRW5ITVJ?
A4-Fuk M{P4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXETWM2OD17LkO2O|AyKM7:TR?= M2Dy[XNCVkeHUh?=
AN3-CA MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTlwNEW0OFQh|ryP Mo\PV2FPT0WU
SK-N-DZ NYfTb4FxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTlwN{K4OFkh|ryP MULTRW5ITVJ?
HSC-2 NFfNZWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTlwN{[2Nlkh|ryP MVnTRW5ITVJ?
EW-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTJXoJsUUN3ME25Mlc6OzZ7IN88US=> NEPhNlFUSU6JRWK=
D-566MG MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\6emlEPTB;OT64N|Y3PCEQvF2= NV3kWJpFW0GQR1XS
COLO-792 MnG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYm3N4pjUUN3ME25Mlk5PzR4IN88US=> Mki1V2FPT0WU
TE-10 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;rNlg6UUN3ME2xNE4xOzl4IN88US=> NYPJOm5uW0GQR1XS
NCI-H650 NUjxWJpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF65SW5KSzVyPUGwMlQzQDZizszN NYnxUGVIW0GQR1XS
U-266 NXra[JNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTFyLkS1OUDPxE1? MnPOV2FPT0WU
Detroit562 NX\sVGRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTFzLkC1NVUh|ryP NFjNUo5USU6JRWK=
NH-12 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2ru[GlEPTB;MUGuNVQ1PiEQvF2= M4i1XHNCVkeHUh?=
CO-314 M1L0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknuTWM2OD1zMT6yPFQzKM7:TR?= MVzTRW5ITVJ?
IST-MEL1 M{jTN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvmW2JOUUN3ME2xNU42OzJ|IN88US=> M2m1THNCVkeHUh?=
KNS-81-FD NV;Ec5dJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTFzLkW1Nlch|ryP MYfTRW5ITVJ?
SW1463 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTFzLkW5PFkh|ryP NHv0[JRUSU6JRWK=
NCI-H23 M3W3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3WzZ2lEPTB;MUGuOlU2OiEQvF2= M3SxT3NCVkeHUh?=
SK-MEL-2 NVr1ZWdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTFzLkexPVch|ryP MmjHV2FPT0WU
NB13 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTmSlhzUUN3ME2xNk4yPDl3IN88US=> Mle0V2FPT0WU
Daoy MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIOxV|BKSzVyPUGyMlI5PTZizszN MWPTRW5ITVJ?
NCI-H1623 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTGTWM2OD1zMj6zPFAyKM7:TR?= NYTnVIhYW0GQR1XS
NMC-G1 NF:xRXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3CTWM2OD1zMj63NVch|ryP NUXLSpFCW0GQR1XS
DK-MG M{LIO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoL1TWM2OD1zMj65OFgzKM7:TR?= M4fx[nNCVkeHUh?=
TCCSUP NHuw[JVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIf1NI1KSzVyPUGzMlEzQDRizszN NHq4[olUSU6JRWK=
SCC-15 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTF|LkK2OVEh|ryP MofuV2FPT0WU
NOS-1 MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWi5eYZkUUN3ME2xN{4zQDl|IN88US=> NGjHOG1USU6JRWK=
RH-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnToTWM2OD1zMz6zNFM4KM7:TR?= NHrnPIRUSU6JRWK=
SK-MEL-3 NIjF[XhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\qd2lEPTB;MUOuN|czQCEQvF2= M2nQb3NCVkeHUh?=
NB5 M3jLdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;KUJlTUUN3ME2xN{41ODZ5IN88US=> MoXsV2FPT0WU
SNU-387 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTQTWM2OD1zMz61NFczKM7:TR?= NXjsfot7W0GQR1XS
CAL-120 Mnf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTF|Lk[3NVgh|ryP MYHTRW5ITVJ?
Mo-T NH3CO4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVW4TVhNUUN3ME2xN{44ODdizszN NY\MOXFVW0GQR1XS
LNCaP-Clone-FGC NVq5SIY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXmTWM2OD1zMz63PVkzKM7:TR?= NHPtXpFUSU6JRWK=
CAN NHq4RlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFziV2FKSzVyPUG0MlAzQDhizszN NI\uU3FUSU6JRWK=
SK-MEL-30 NIL6TXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTF2LkC2N{DPxE1? MVzTRW5ITVJ?
COLO-678 NUXWRnZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEK3cYFKSzVyPUG0MlA5OjJizszN M3XoXnNCVkeHUh?=
SCC-9 Mn3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkL6TWM2OD1zND6xNFIyKM7:TR?= MlTwV2FPT0WU
KINGS-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLaN5FKSzVyPUG0MlE1ODJizszN NVLscYFyW0GQR1XS
SL-513 NX7uO5IzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LpO2lEPTB;MUSuNVg4KM7:TR?= M{fNbnNCVkeHUh?=
HLE NH2zZldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvqRZJKSzVyPUG0MlM5PTJizszN NFTyd2tUSU6JRWK=
SW1573 NFfTdnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3UTWM2OD1zND60OFM2KM7:TR?= M3\QZ3NCVkeHUh?=
KYSE-140 NELyW4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\JcFJ5UUN3ME2xOE43OzJ5IN88US=> NWK1d3ZtW0GQR1XS
SK-PN-DW NGLtT3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzaNlJZUUN3ME2xOE45ODBzIN88US=> NXfje|ZWW0GQR1XS
A253 MkTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTF3LkC2NlUh|ryP NYe2[mJMW0GQR1XS
CAL-12T NGP5UmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3ezb2lEPTB;MUWuOFY3OiEQvF2= NHXhfpFUSU6JRWK=
COLO-679 MlG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTF3Lke2PFMh|ryP MV\TRW5ITVJ?
UACC-257 NWT2ZYpRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHtOoNlUUN3ME2xOk4yOjBzIN88US=> M2\V[XNCVkeHUh?=
U-87-MG M1z3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TxcmlEPTB;MU[uN|UzOyEQvF2= M1ixOHNCVkeHUh?=
HCC1806 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jGUWlEPTB;MU[uO|A4OSEQvF2= MmLPV2FPT0WU
NCI-H2170 NEXiWWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWj6WJZqUUN3ME2xO{4zPDR6IN88US=> MmW1V2FPT0WU
AGS MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHQeWJKSzVyPUG3MlM5ODhizszN MoPNV2FPT0WU
MEL-HO M3[zPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33HfWlEPTB;MUeuO|UxOyEQvF2= MWHTRW5ITVJ?
SW48 M3zxXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTF5Lke3NVYh|ryP MXjTRW5ITVJ?
HuP-T4 M4\YSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTF6LkCyNFYh|ryP MVTTRW5ITVJ?
NCI-H720 M3j6O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HuNGlEPTB;MUiuNVQxOiEQvF2= NHr1[YVUSU6JRWK=
RCC10RGB MnW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{H0W2lEPTB;MUiuNVY6PyEQvF2= NWXmS5k4W0GQR1XS
HD-MY-Z MofkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnn2TWM2OD1zOD6yNlU1KM7:TR?= NGjvVpZUSU6JRWK=
A427 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHhTWM2OD1zOD61NFk1KM7:TR?= MYjTRW5ITVJ?
HCC2998 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDNOmRKSzVyPUG4MlYxPTFizszN NX;zSWJiW0GQR1XS
EPLC-272H NH7LeYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFKwZm5KSzVyPUG5MlA1OzRizszN M{XmZXNCVkeHUh?=
C32 MlP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTF7LkC0OUDPxE1? MWXTRW5ITVJ?
UMC-11 NHy4coFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7kRVZKSzVyPUG5MlIyOjNizszN MYHTRW5ITVJ?
CaR-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjLNWtKSzVyPUG5MlY5ODRizszN MlLmV2FPT0WU
KYSE-410 NVTiToFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmX0TWM2OD1zOT65NVM6KM7:TR?= MUTTRW5ITVJ?
HuCCT1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjnTWM2OD1{MD62Nlk1KM7:TR?= MWrTRW5ITVJ?
LB996-RCC M{DXdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoT6TWM2OD1{MD63NVY5KM7:TR?= NH\jWnZUSU6JRWK=
KYSE-70 M1L6e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1yzc2lEPTB;MkCuPFA2QSEQvF2= MX3TRW5ITVJ?
CAL-72 NHTTOI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTJyLkmxOUDPxE1? M4rQVXNCVkeHUh?=
Capan-2 M2XpdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTrTWM2OD1{MT6wOFE{KM7:TR?= Mlf6V2FPT0WU
PANC-08-13 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\KeXJHUUN3ME2yNU4zPTF3IN88US=> NGHZeIpUSU6JRWK=
SBC-1 NIDUW5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PTbmlEPTB;MkGuN|A5OSEQvF2= NVrSS2pjW0GQR1XS
MFM-223 M2jvTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDPcopKSzVyPUKxMlM{PDJizszN NYe2TGl2W0GQR1XS
BB49-HNC NU[0e4V6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkKxTWM2OD1{MT61O|E3KM7:TR?= NX32dZNGW0GQR1XS
SH-4 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M123XGlEPTB;MkGuOlYyQCEQvF2= NELIbmZUSU6JRWK=
HuO9 NEjWXJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTJzLkm4NlUh|ryP MnPDV2FPT0WU
AM-38 M2rKd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PxdGlEPTB;MkKuNFQ5PSEQvF2= M3qwbHNCVkeHUh?=
A431 M2XnVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjYfYZjUUN3ME2yN{4zOTF7IN88US=> NUPYPXpOW0GQR1XS
YAPC M3\UTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjhWVhKSzVyPUKzMlI3PTFizszN NYW2R4Y4W0GQR1XS
LU-139 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrGVXdKSzVyPUKzMlQ5ODlizszN NXLWNlBWW0GQR1XS
HEC-1 M4fI[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTJ|LkS5N|ch|ryP NV\5Z5F6W0GQR1XS
SCC-25 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTJ2LkOwNFYh|ryP MorrV2FPT0WU
HT-29 M3u4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTabIJkUUN3ME2yOE4{QDJ|IN88US=> M3P3e3NCVkeHUh?=
PC-14 MoTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHqNYtKSzVyPUK0MlY2PzFizszN NVTuVVlYW0GQR1XS
Calu-6 MlrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDyT2VYUUN3ME2yOU42ODdzIN88US=> NVHNeGNGW0GQR1XS
SJRH30 M2\wfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nqOGlEPTB;MkWuOlQ6PiEQvF2= NHr5N|FUSU6JRWK=
ChaGo-K-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\oVXRiUUN3ME2yOk4yPjJ7IN88US=> MV;TRW5ITVJ?
IA-LM MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWq5[GpoUUN3ME2yOk4{PjR3IN88US=> MULTRW5ITVJ?
GP5d MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1m5eWlEPTB;Mk[uOFQ6OSEQvF2= MV3TRW5ITVJ?
NCI-H2291 NHHyc2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLRfG1uUUN3ME2yOk43PTRzIN88US=> M{DVWXNCVkeHUh?=
BALL-1 MmLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTST21iUUN3ME2yOk46Ozl5IN88US=> MknOV2FPT0WU
HCC1954 NEnLVpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrHfHdKSzVyPUK2Mlk5ODhizszN MkfzV2FPT0WU
NCI-H2452 NEXlSGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnte4p1UUN3ME2yO{41OTZ|IN88US=> M3G0VHNCVkeHUh?=
LU-99A NVLifXJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4W5SGlEPTB;MkeuOVU5OiEQvF2= NFnpUWxUSU6JRWK=
NTERA-S-cl-D1 NFPjR5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2H3VWlEPTB;MkeuO|I6QSEQvF2= MYTTRW5ITVJ?
PANC-10-05 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPlTWM2OD1{Nz63O|c2KM7:TR?= M3X4ZnNCVkeHUh?=
NCI-H2405 Ml71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XRT2lEPTB;MkeuPVM5PyEQvF2= M3nab3NCVkeHUh?=
MDA-MB-415 NXvqVoZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfzb4RKSzVyPUK4MlQyOzdizszN NEDIeHpUSU6JRWK=
NCI-H2342 NFzpPFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvzT|RKSzVyPUK4MlUzQDFizszN MXXTRW5ITVJ?
TGBC24TKB M1;RSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLuRVB7UUN3ME2yPE44OTF5IN88US=> NFLuNnpUSU6JRWK=
LU-134-A MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7TfJpKSzVyPUK4MlkzPjFizszN Mk\UV2FPT0WU
SCC-4 NFjubpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTNzLkC0PVQh|ryP NG\tUJlUSU6JRWK=
Saos-2 M4e2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTNzLkmzNFYh|ryP NUTrdlNJW0GQR1XS
RERF-LC-MS MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TNfGlEPTB;M{KuPFI{OSEQvF2= MnvaV2FPT0WU
M14 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTN{Lkm3OlQh|ryP NW\1PY5qW0GQR1XS
HPAF-II MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2H6eGlEPTB;M{OuOVAyOSEQvF2= MmnkV2FPT0WU
NCI-H1755 Mle5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvEOHd[UUN3ME2zOE4{OzB3IN88US=> MlztV2FPT0WU
D-392MG MoXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTN3Lki2O|Qh|ryP NIW3d|FUSU6JRWK=
A704 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DGeGlEPTB;M{[uNFQzPyEQvF2= NYTUc4toW0GQR1XS
CP50-MEL-B MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTN4LkG5NVEh|ryP NEHoc2pUSU6JRWK=
EW-18 M3LDfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW[3SVZVUUN3ME2zOk41PTJizszN NFT2cYdUSU6JRWK=
WM-115 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonqTWM2OD1|Nj64NFk6KM7:TR?= NWfBcpp2W0GQR1XS
LU-65 NV\oPFJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXlTWM2OD1|Nz6xOFE4KM7:TR?= MVvTRW5ITVJ?
NCI-H1563 MojRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoToTWM2OD1|Nz6yOFg1KM7:TR?= NH7r[VFUSU6JRWK=
DBTRG-05MG Mn:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGn5ZWlKSzVyPUO4MlA3QTFizszN NGfpcG5USU6JRWK=
NCI-H630 NX3uNWExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTN6LkS3NVQh|ryP NXHGU3A6W0GQR1XS
NCI-H1155 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzOTWM2OD1|OT6yOFIh|ryP NH3zbIdUSU6JRWK=
OVACR-3 NW\kU4o{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPDSpNKSzVyPUO5MlkyQTVizszN M3fjcnNCVkeHUh?=
OAW-42 MlHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHQO5hWUUN3ME20NE41OjV6IN88US=> NHfXe4NUSU6JRWK=
JVM-2 NHuwVlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEG3dZZKSzVyPUSxMlI1OTVizszN MmC5V2FPT0WU
C3A M3;BXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DlTWlEPTB;NEGuN|Q1PyEQvF2= Mn3MV2FPT0WU
HT55 M1rsWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHvTWM2OD12Mj6yPFQyKM7:TR?= NFvTW3pUSU6JRWK=
OVCAR-4 MkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nOe2lEPTB;NEKuNlk4PCEQvF2= NYHQTo9[W0GQR1XS
MEG-01 M1nj[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;Be|dkUUN3ME20Nk41PjF4IN88US=> MWTTRW5ITVJ?
NCI-H82 NHPWe2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4f0TGlEPTB;NEOuPVg6OiEQvF2= M{XDWnNCVkeHUh?=
JEG-3 NFTT[npIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWroc5ZzUUN3ME20OE46PDdizszN NW\ISGtMW0GQR1XS
BPH-1 MkLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETOVGpKSzVyPUS2MlM6QThizszN NIHTcolUSU6JRWK=
MPP-89 NWDTTnBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\GVHF4UUN3ME20O{4zQDl6IN88US=> NVjoU|BpW0GQR1XS
ALL-PO MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTR5LkSxPFgh|ryP MU\TRW5ITVJ?
HT MlTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{f2fWlEPTB;NEeuOFkzKM7:TR?= M3nPfXNCVkeHUh?=
NCI-H2347 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rqbGlEPTB;NEiuNFcyPSEQvF2= MWHTRW5ITVJ?
A2780 MnmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjCTWM2OD12OT60NlI5KM7:TR?= NH;NTFBUSU6JRWK=
KARPAS-299 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELHZ3VKSzVyPUS5MlUyOTlizszN Mmj5V2FPT0WU
NCI-H1651 NH;PRmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHiwOm9KSzVyPUS5Mlg5OjFizszN NIPxNINUSU6JRWK=

... Click to View More Cell Line Experimental Data

体内研究 150 mg/kg PD 0332991处理 MDA-MB-435移植瘤完全抑制肿瘤。在多种人类肿瘤移植瘤中,PD 0332991也显示广谱抗癌活性,通过除去血管中p-Rb和增殖Marker Ki-67,且调节基因使其处于E2F转录水平控制。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

Cdk实验:

PD0332991溶解在DMSO中。在96孔板上进行CDK 实验。通过杆状病毒感染,所有的CDK-cyclin 激酶复合体 在昆虫细胞中表达。实验底物为与GST融合的一段pRb。每孔体积为0.1 ml,包含:终浓度为20 mm Tris-HCl(pH 为7.4), 50 mmNaCl, 1 mm二硫苏糖醇, 10 mmMgCl2, 25 μm ATP (用于CDK4-cyclin D1, CDK6-cyclin D2,和CDK6-cyclin D3)或12 μm ATP (用于CDK2-cyclin E, CDK2-cyclin A, 和CDC2-cyclin B),0.25 μCi [γ-32P]ATP, 20 ng 酶, 1 μg GST·RB-Cterm, 及PD 0332991 (0.001-0.1μM)。除了[γ-32P]ATP的所有混合物加到孔中,放在搅拌器上搅拌2分钟。加入 [γ-32P]ATP开始反应, 在25 oC下温育15分钟。加入0.1 ml 20% 三氯乙酸终止反应, 在4 oC维持至少1小时,使底物沉淀。用0.2 ml 10%三氯乙酸冲洗5次,用β-计数器板测定掺入的放射性。
细胞实验:

[1]

+ 展开
  • Cell lines: MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM,和K562细胞
  • Concentrations: 0.01-1 μM
  • Incubation Time: 24小时
  • Method:

    肿瘤细胞包括MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM,及K562按每孔2×104个细胞接种在96孔板上,温育过夜。加入PD 0332991 (0.01-1 μM) ,37oC温育24小时。每孔加入[14C]胸甘(0.1 μCi) ,进行同位素示踪,持续72小时。用β-计数器板测定掺入的放射性。


    (Only for Reference)
动物实验:

[1]

+ 展开
  • Animal Models: 携带晚期人类肿瘤移植瘤,包括结肠-205, MDA-MB-435 乳腺癌, SF-295 恶性胶质瘤, ZR-75-1 乳腺癌, PC-3 前列腺癌, H125 肺癌, SW-620结肠癌, H23肺癌,及MDA-MB-468 乳腺癌 (Rb 阴性)的SCID鼠
  • Formulation: 溶解在乳酸钠buffer(50 mM, pH 4.0)中
  • Dosages: 0-150 mg/kg
  • Administration: 口服饲喂
    (Only for Reference)

溶解度 (25°C)

体外 Water 30 mg/mL (61.98 mM)
DMSO 3 mg/mL warmed (6.19 mM)
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
Saline
6 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 483.99
化学式

C24H29N7O2.HCl

CAS号 827022-32-2
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03709680 Not yet recruiting Solid Tumors|Ewing Sarcoma|Rhabdoid Tumor|Rhabdomyosarcoma|Neuroblastoma|Medulloblastoma Pfizer February 5 2019 Phase 1
NCT03609047 Not yet recruiting Breast Cancer Stage II|Breast Cancer Stage III European Organisation for Research and Treatment of Cancer - EORTC|Pfizer January 7 2019 Phase 2
NCT03691493 Not yet recruiting Anatomic Stage IV Breast Cancer AJCC v8|Estrogen Receptor Positive|HER2/Neu Negative|Metastatic Breast Carcinoma|Metastatic Malignant Neoplasm in the Bone|Progesterone Receptor Positive|Prognostic Stage IV Breast Cancer AJCC v8 Emory University|Pfizer December 1 2018 Phase 2
NCT03530696 Not yet recruiting HER2-positive Breast Cancer|Breast Cancer|Breast Cancer Stage|Recurrent Breast Cancer|Metastatic Breast Cancer|HER2 Positive Breast Carcinoma University of Arizona|Pfizer November 30 2018 Phase 2
NCT03531645 Not yet recruiting Malignant Neoplasms of Female Genital Organs M.D. Anderson Cancer Center|AstraZeneca|Pfizer November 2018 Phase 2
NCT03644186 Not yet recruiting Breast Cancer|Estrogen Receptor Positive Tumor|HER2-positive Breast Cancer International Breast Cancer Study Group|Pfizer|Hoffmann-La Roche October 2018 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

相关CDK产品

Tags: 购买Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl供应商 | 采购Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl价格 | Palbociclib (PD-0332991) HCl生产 | 订购Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID